InvestorsHub Logo
Followers 37
Posts 6828
Boards Moderated 1
Alias Born 09/06/2014

Re: Duke2484 post# 89573

Thursday, 12/08/2016 9:23:14 AM

Thursday, December 08, 2016 9:23:14 AM

Post# of 328795
My point, BTW, is: the average investor doesn't know how to interpret the results of clinical trials.

When a trial misses its primary endpoint and the company releases a PR bragging about the secondary endpoints or cherry-picking data, the average investor can be fooled into thinking the trial was a success.

That's my point.

The FDA, however, is never fooled by trials that miss their primary endpoints. Neither are you and I.